16 assets in Metastatic Malignant Neoplasm In The Lymph Nodes

Therapeutic assets addressing Metastatic Malignant Neoplasm In The Lymph Nodes, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Adriamycin Metastatic Malignant Neoplasm In The Lymph Nodes	Laura M. Spring, MD	P3	BB (67)
Cyclophosphamide Metastatic Malignant Neoplasm In The Lymph Nodes	Laura M. Spring, MD	P3	BB (66)
Indocyanine Green Metastatic Malignant Neoplasm In The Lymph Nodes	Isabelle Henskens	P4	BB (65)
Cabozantinib Metastatic Malignant Neoplasm In The Lymph Nodes	National Cancer Institute (NCI)	P3	B (60)
Nivolumab Metastatic Malignant Neoplasm In The Lymph Nodes	National Cancer Institute (NCI)	P3	B (60)
Ipilimumab Metastatic Malignant Neoplasm In The Lymph Nodes	National Cancer Institute (NCI)	P3	B (59)
Binimetinib Metastatic Malignant Neoplasm In The Lymph Nodes	ECOG-ACRIN Cancer Research Group	P2	CCC (53)
Capecitabine Metastatic Malignant Neoplasm In The Lymph Nodes	Laura M. Spring, MD	P2	CCC (53)
Carboplatin Metastatic Malignant Neoplasm In The Lymph Nodes	Tang-Du Hospital	P2	CCC (53)
Encorafenib Metastatic Malignant Neoplasm In The Lymph Nodes	ECOG-ACRIN Cancer Research Group	P2	CCC (53)
Pembrolizumab Metastatic Malignant Neoplasm In The Lymph Nodes	Laura M. Spring, MD	P2	CCC (53)
18f-flt Metastatic Malignant Neoplasm In The Lymph Nodes	ECOG-ACRIN Cancer Research Group	P2	CCC (52)
NRT6008 Metastatic Malignant Neoplasm In The Lymph Nodes	Chengdu New Radiomedicine Technology Co. LTD.	P1	CC (43)
Carbon Nanoparticle Suspension Metastatic Malignant Neoplasm In The Lymph Nodes	Second Affiliated Hospital, School of Medicine, Zhejiang University	N/A	D (30)
Tuvonralimab Metastatic Malignant Neoplasm In The Lymph Nodes	Tang-Du Hospital	N/A	D (30)
Aipalolitovorelizumab Metastatic Malignant Neoplasm In The Lymph Nodes	The First Affiliated Hospital with Nanjing Medical University	N/A	NR ()